All In Biotech

Drug Trial Radar · NCT01772472

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy

Last checked: Nov 20, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,486 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,486

Actual

Start

Apr 3, 2013

Primary completion

Jul 25, 2018

Study completion May 23, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
NSABP Foundation Inc; GBG Forschungs GmbH
First posted
Jan 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.

Conditions

  • Breast Cancer

Interventions

  • trastuzumabDrug

    6 mg/kg intravenously every 3 weeks, 14 cycles

  • trastuzumab emtansineDrug

    3.6 mg/kg intravenously every 3 weeks, 14 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-free Survival (IDFS) Rate at 3 YearsTime frame: At Year 3

Locations

268 sites in 28 countries. Site status is shown where the registry gives one.

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Todd Cancer Institute at Long Beach Memorial Medical Center

    Long Beach, California

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford University Medical Center

    Palo Alto, California

  • Kaiser Permanente - San Diego

    San Diego, California

  • Breastlink Medical Group Inc

    Santa Ana, California

  • Kaiser Permanente - Vallejo

    Vallejo, California

  • Kaiser Permanente - Franklin

    Denver, Colorado

  • Colorado Cancer Research Program/Admin

    Denver, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Washington Cancer Institute

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • UF Health Orlando

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Edward Cancer Center Naperville

    Naperville, Illinois

  • Edward Cancer Center Plainfield

    Plainfield, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Norton Healthcare Inc.

    Louisville, Kentucky

  • Cancer Care of Maine

    Brewer, Maine

  • New England Cancer Specialists

    Scarborough, Maine

  • Mercy Medical Center

    Baltimore, Maryland

  • Greater Baltimore Medical Center

    Baltimore, Maryland

  • Med Star Franklin Square Medical Center/Weinburg Cancer Institute

    Baltimore, Maryland

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Spectrum Health Hospitals

    Grand Rapids, Michigan

  • Breslin Cancer Center

    Lansing, Michigan

  • William Beaumont Hospital

    Royal Oak, Michigan

  • US oncology research at Minnesota Oncology

    Saint Louis Park, Minnesota

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Sparta Cancer Center

    Sparta, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Troy Cancer Treatment Program

    Troy, New York

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Sanford Roger Maris Cancer Center

    Fargo, North Dakota

  • Aultman Hospital

    Canton, Ohio

  • Fairview Hospital

    Cleveland, Ohio

Showing 40 of 268 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.